Precision Medicine

A breakthrough program at Children's Hospital of Philadelphia is redefining heart pumps as tools for recovery, not just a bridge to transplant.

Wolters Kluwer's UpToDate again tops KLAS rankings, highlighting a major trend: integrating expert-backed patient education directly into clinical care.

A landmark acquisition aims to fix trial diversity and access by moving research from far-off labs into your neighborhood doctor's office. Here's why it matters.

As GLP-1 drugs dominate, Veru Inc. advances a novel therapy to combat muscle loss, aiming for a new standard of 'quality' weight loss in older adults.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

Beyond Cancer is set to reveal early human trial data for its novel nitric oxide therapy, a move that could expand its parent company into oncology.

For the second straight year, Collette Health is #1 in virtual care. Discover how its integrated platform is redefining hospital efficiency and patient safety.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.

Celcuity prepares for a key fireside chat at Guggenheim's 2026 summit, with investors eyeing crucial updates on its lead cancer drug, gedatolisib.

With promising new pipeline data and a major earnings report looming, Aclaris Therapeutics heads to two investor summits, placing its strategy on display.

Following promising early results, RESTEM's Restem-L cell therapy enters a pivotal Phase 2/3 trial, aiming to transform treatment for IIM patients.

Precision medicine firm Atropos Health joins NY's elite digital health startups, signaling a market shift toward scalable, data-driven healthcare solutions.

With a key drug for a rare disease nearing the finish line, Spruce adds two industry veterans to navigate the high-stakes FDA approval process.

An independent analysis shows a specialized OB/GYN staffing model improves maternal outcomes, lowers C-section rates, and delivers a significant return on investment.

Current blood thinners carry a risky trade-off. A new class of drugs targeting Factor XIa could prevent deadly clots without the dangerous bleeding.

Industrial giant AMETEK acquires LKC Technologies, aiming to revolutionize eye care with portable diagnostic devices for early disease detection.

Relay Therapeutics' experimental drug, zovegalisib, offers new hope for a common and hard-to-treat form of advanced breast cancer with a promising safety profile.

A New Mexico health system is betting on a full-scale AI rollout to reduce doctor burnout, improve patient care, and boost its bottom line.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.